ARTICLE | Clinical News
Trabedersen: Phase IIb data
November 15, 2010 8:00 AM UTC
An open-label, international Phase IIb trial in 134 evaluable patients with recurrent or refractory anaplastic astrocytoma or GBM showed that 10 µM trabedersen non-significantly improved tumor control...